Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Lack of Concordance Regarding Plasma Testing in Lung Cancer Must Be Overcome

February 16th 2021

Andrew Mckenzie, PhD, discusses the differences between tissue- and plasma-based NGS tests, factors that can lead to a lack of concordance, and important areas of ongoing research.

Lurbinectedin/Irinotecan Shows Impressive Antitumor Activity in Relapsed SCLC

February 15th 2021

February 15, 2021 - The combination of lurbinectedin and irinotecan following relapse on frontline treatment was found to induce promising antitumor activity in patients with small cell lung cancer.

Recognizing the Value of Radiation Therapy in Lung Cancer

February 14th 2021

Randy Stevens, MD, discusses the growing role for radiation in lung cancer, delivery techniques, and adverse effect management strategies.

Dr. Weiss on the FDA Approval of Trilaciclib in Small Cell Lung Cancer

February 12th 2021

Jared Weiss, MD, discusses the FDA approval of trilaciclib in small cell lung cancer.

FDA Approves Trilaciclib to Reduce Chemo-Induced Bone Marrow Suppression in ES-SCLC

February 12th 2021

February 12, 2021 - The FDA has approved trilaciclib to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer.

Dr. Brahmer on Emerging Targeted Therapies in EGFR Exon 20–Mutated Lung Cancer

February 10th 2021

Julie R. Brahmer, MD, discusses emerging targeted therapies for patients with lung cancer who harbor EGFR exon 20 insertion mutations.

Dr. Fidler on Balancing Benefit of Novel Agents in EGFR Exon 20–Mutant NSCLC With Toxicities

February 10th 2021

Mary Jo J. Fidler, MD, discusses the potential for novel agents in EGFR exon 20–mutated non–small cell lung cancer.

Dr. Jänne on the Promise of Mobocertinib in EGFR Exon 20–Mutant NSCLC

February 10th 2021

Pasi A. Jänne, MD, PhD, discusses the rationale for exploring mobocertinib in EGFR exon 20–mutated non–small cell lung cancer.

Borghaei Breaks Down Choices in Immunotherapy Approaches in Lung Cancer

February 8th 2021

With the emergence of multiple immunotherapy approaches in recent years, the decision of whether to use a single agent, to pair it with chemotherapy, or to pair it with another immunotherapy agent has come to the forefront of treatment.

Dr. Brahmer on Determining When to Start Immunotherapy in Frontline NSCLC

February 8th 2021

Julie R. Brahmer, MD, discusses factors to consider when determining when to initiate immunotherapy in a patient with newly diagnosed non–small cell lung cancer.

Dr. Raez on the Potential Utility of Cemiplimab in NSCLC

February 8th 2021

Luis E. Raez, MD, discusses the potential utility of cemiplimab-rwlc in non–small cell lung cancer.

Strategizing Effective Ways to Overcome TKI Resistance in ALK+ NSCLC

February 8th 2021

Vincent Lam, MD, describes frontline indications for this patient population, as well as strategies that can be utilized to overcome TKI resistance in later lines of therapy.

Forde Recaps Chemoimmunotherapy Activity in PD-L1–Negative NSCLC

February 8th 2021

Immunotherapy plus chemotherapy is a standard of care for patients with advanced PD-L1–negative non–small cell lung cancer who do not harbor actionable driver mutations.

Future of Frontline EGFR+ NSCLC Features TKI, Chemo Combos and Improved Molecular Profiling

February 7th 2021

Synergizing EGFR TKIs with antiangiogenic agents and chemotherapy, as well as improving the use of molecular classification, are novel strategies aimed at taking the frontline setting for patients with EGFR-mutant non–small cell lung cancer to the next level.

Durvalumab Delivers Durable Benefit, Regardless of PD-L1 Expression, in NSCLC

February 7th 2021

Mark A. Socinski, MD, discusses the nuances of the PACIFIC trial and ongoing research with durvalumab that could extend the reach of immunotherapy in early-stage lung cancer.

ADAURA Raises Questions About Optimal Use of Adjuvant EGFR TKIs in NSCLC

February 6th 2021

Over the past 2 decades, the field of EGFR-mutated non–small cell lung cancer has grown tremendously, but the influx of data and the recent regulatory approval of adjuvant osimertinib have raised several important questions to be addressed to ensure that the optimal treatment approach is utilized.

Lung Cancer Paradigm Pushes Toward Accessible Care and Improved Telemedicine

February 6th 2021

Rogerio C. Lilenbaum, MD, discusses some of the key clinical issues facing the lung cancer field, the role of genomic testing and multidisciplinary care, and the challenges that arose with telemedicine during the coronavirus disease 2019 pandemic.

Experts Take Stock of Critical Clinical Issues in Lung Cancer

February 6th 2021

In the quest for scientific purity, one should not lose sight of the meaningful end points that can make a difference in patients’ daily lives.

Dr. Fidler on the Potential Utility of ctDNA to Inform Treatment Escalation in Lung Cancer

February 6th 2021

Mary Jo J. Fidler, MD, discusses the potential utility of circulating tumor DNA to inform treatment escalation in lung cancer.

Dr. Lilenbaum on the Challenges of Integrating Telehealth Services in Lung Cancer

February 6th 2021

Rogerio C. Lilenbaum, MD, discusses the challenges of integrating telehealth services in lung cancer.